OraSure Technologies (OSUR) Registration Filing summary

Company overview and business model

• Develops, manufactures, markets, and sells diagnostic products and specimen collection devices using proprietary technologies, including rapid tests for HIV, Hepatitis C, Syphilis, and COVID-19, sold to clinical labs, hospitals, government agencies, and OTC markets in the U.S. and internationally.

• Offers sample management solutions for clinical labs, researchers, pharma, and animal health, with products for disease risk management, diagnostics, and the microbiome market.

• Discontinued the risk assessment product line in Q2 2025, with related asset sales completed in Q1 2025.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, with allocation details to be provided in future prospectus supplements.

Risk factors and disclosures

• Investment involves high risk, including business, operational, regulatory, and market uncertainties, as detailed in incorporated SEC filings.

• Risks include market acceptance, customer concentration, manufacturing, regulatory compliance, competition, funding, supply chain, litigation, and economic conditions.

• Forward-looking statements are subject to significant uncertainties and actual results may differ materially.